· Form D filing · Baseline
Reported sold as filed: $12,000,000 · Offering amount as filed: $12,000,000
SEC source checked 29 Oct 2026. This is the issuer’s historical filing, not a current valuation.
View original evidence ↗Adela, Inc.
On its website, the company describes its work as “Best-in-class technology. Tissue-free detection. Adela is advancing the field of epigenomics to transform how cancer is detected and monitored. By leveraging proprietary methylome analysis technology…”.
- Industry
- Biotechnology
- Tracked VC backers
- 0
- Location
- Not recorded
Publicly documented VC backing
These sources establish that the firm lists the company. The observation date records when RiseFinder captured the relationship; it does not establish when the investment happened.
No tracked VC backing is recorded.